Coronavirus /Biotechnology Stock News Bites
- Tiziana
Life Sciences (NASADAQ: $TLSA) To Expedite Development of its
Fully Human Anti-Interleukin-6-Receptor Monoclonal Antibody, a Potential
Treatment of Certain Patients Infected with Coronavirus COVID-19
Investorideas.com
(www.investorideas.com) _ Coronavirus
/Biotech (COVID-19) Stock News Bites- New York/London, March 11,
2020 - Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS)
("Tiziana" or the "Company"), a biotechnology company
focused on innovative therapeutics for inflammatory and autoimmune diseases,
announced today that it is expediting development of TZLS-501, a
novel, fully human anti-interleukin-6 receptor (anti-IL6R)
monoclonal antibody (mAb) for treatment of patients infected with coronavirus
COVID-19 (SARS-CoV-2). Tiziana plans to
administer TZLS-501 using a proprietary formulation technology. The Company entered into a
world-wide license for composition-of-matter of TZLS-501, a fully human mAb
targeting IL-6R, with Novimmune, SA, a Swiss
biotechnology company in 2017.
Certain patients infected with coronavirus COVID-19 may develop an
uncontrolled immune response ("cytokine storm") resulting in severe
damage to lung tissue which could lead to respiratory failure (see Note 1,
below). Early clinical studies conducted by doctors in China suggest
that anti-IL6R mAbs may be used in clinical practice for treatment of COVID-19.
Consequently, China'sNational Health Commission has recommended
the use of Roche's blockbuster drug, Actemra® for treatment of patients
infected with COVID-19, with serious lung damage and elevated IL-6 levels.
Actemra was first approved by the FDA in 2010 for rheumatoid arthritis. Besides Actemra®, Sanofi
and Regeneron are currently exploring Kevzara®, an FDA-approved anti-IL-6 receptor therapy for rheumatoid arthritis,
for treatment of severe COVID-19.
Tiziana's anti-IL-6R mAb binds to both the membrane-bound
and soluble forms of IL-6R and rapidly depletes circulating levels of IL-6 in
the blood (see Note 2, below). An excessive production of IL-6 is
regarded as a key driver of chronic inflammation and is believed to be
associated with severe lung damage observed with COVID-19 infections and acute
respiratory illness. A recent Chinese study also reported that COVID-19 infection caused clusters of severe respiratory illness such as
severe acute respiratory distress syndrome (ARDS) (see Note 3, below).
"We believe that the features of TZLS-501
consisting of its dual mechanism of action to inhibit signaling by the
membrane-bound and soluble IL-6 receptors along with rapid depletion of
circulating IL-6 cytokine, a major cause of lung damage, provides TZLS-501 with
distinct advantages for treatment of COVID-19 over other anti-IL-6R mAbs such
as Actemra® and Kevzara® for
treatment of COVID-19. The recent decision by
researchers in China to add Actemra® to treatment guidelines for
coronavirus patients with serious lung damage confirms the utility of anti-IL6R
mAb. We are excited to move forward with our clinical development plan to
expedite evaluation in patients as soon as possible", said Dr. Kunwar
Shailubhai, CEO & CSO of Tiziana Life Sciences.
Read the company’s full news and
disclaimer here:
Visit Investorideas.com biotech and
coronavirus stocks directory https://www.investorideas.com/BIS/stock_list.asp
About Investorideas.com
- News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing
third party news, research and original financial content. Learn about
investing in stocks and sector trends with our news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns :
Crypto Corner , Play by Play sports and stock news column,
Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate
Change , Exploring Mining
the AI Eye .
Stock Bites is a branded product of
Investorideas.com Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Disclosure is posted for each
compensated news release, content published /created if required but otherwise
the news was not compensated for and was published for the sole interest of our
readers and followers. Contact management and IR of each company directly
regarding specific questions. This stock bites news release
publication is available as a paid for
service on Investorideas.com https://www.investorideas.com/News-Upload/
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Get free
investor news alerts
Contact Investorideas.com
800 665 0411
